The Hidden Financial Drain of “Normal” Echoes: Why VBC Organizations Must Rethink Heart Failure Detection

In value-based care (VBC), a missed diagnosis isn’t just a clinical oversight—it is a massive operational and financial liability. Primary care providers frequently rely on standard echocardiograms to detect heart failure (HF). But because an echo is a structure imaging tool looking for a hemodynamic problem, it often misses early-stage disease.

When structural changes lag behind underlying hemodynamics, standard echo workflows fail the patient, and the financial ripple effects for VBC organizations are significant. Here is why upgrading your diagnostic approach is a financial imperative.

Relying solely on structural imaging to rule out a hemodynamic disease inevitably leaves high-risk patients undiagnosed until a crisis occurs. In fact, 65% of Medicare patients first diagnosed with heart failure^1,2 receive that diagnosis in the ER or an inpatient setting, and a staggering 77% of all HF-related costs stem from hospitalization.³

When a typical echo report concludes “within normal limits” or “no clinically significant findings”—despite raw data indicating early dysfunction—the critical window for early intervention is lost. Catching elevated filling pressures early in the primary care setting shifts the paradigm. By diagnosing HF in the outpatient setting rather than during an acute inpatient admission, organizations can curb the massive downstream costs associated with late-stage disease and avoidable hospitalizations.

Under the CMS RAF-HCC v28 model, accurately capturing and documenting patient acuity is more critical than ever. The vague, non-committal language often found in standard echo reports—like “may represent age-related changes” versus “early dysfunction—forces PCPs to make the final clinical call without definitive evidence. This ambiguity frequently results in missed diagnoses and under-coding a patient’s true risk.

Implementing pragmatic diagnostics like the Vivio System changes this dynamic. A positive Vivio test—when coupled with the results of the embedded KCCQ-12 and appropriate chart documentation—allows for the submission of ICD-10 I50.1, which continues to map to HCC 226 under the current CMS RAF-HCC v28 model. This ensures that the VBC organization is accurately funded to manage the patient’s complex needs.

Risk Adjustment Data Validation (RADV) audits demand objective, unassailable chart documentation. If a VBC organization codes for heart failure based on a “borderline” echo report that actively defers the diagnostic call, they expose themselves to significant compliance risks and financial clawbacks.

Echocardiograms are highly subjective, susceptible to signal noise, and have up to a 30% discordance in diastolic grading between human readers. You cannot confidently defend an HCC code built on a guess. In contrast, the Vivio System is an FDA-cleared Class II medical device that provides an objective indication of elevated left ventricular end-diastolic pressure (LVEDP) in under five minutes. By replacing interpretive imaging guesswork with definitive physiologic data, VBC organizations can confidently substantiate their clinical diagnoses and protect their organization during strict chart reviews.